AbCellera Biologics Inc. Share-based Payment Arrangement, Expense
AbCellera Biologics Inc. (ABCL) reported Share-based Payment Arrangement, Expense of $12.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- AbCellera Biologics Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $12.29M, a 13.53% decline year-over-year.
- AbCellera Biologics Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $12.01M, a 18.75% decline year-over-year.
- AbCellera Biologics Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $12.90M, a 15.25% decline year-over-year.
- AbCellera Biologics Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $13.89M, a 19.05% decline year-over-year.
- AbCellera Biologics Inc. share-based payment arrangement, expense for fiscal 2025 was $55.79M, a 17.44% decline from fiscal 2024.
- AbCellera Biologics Inc. share-based payment arrangement, expense for fiscal 2024 was $67.58M, a 5.29% increase from fiscal 2023.
- AbCellera Biologics Inc. share-based payment arrangement, expense for fiscal 2023 was $64.18M, a 29.71% increase from fiscal 2022.
- AbCellera Biologics Inc. share-based payment arrangement, expense for fiscal 2022 was $49.48M, a 61.46% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.29M 10-Q · filed 2026-08-05 | $24.30M 10-Q · filed 2026-08-05 | $37.20M derived: sum of 3 quarters · filed 2026-08-05 | $51.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $12.01M 10-Q · filed 2026-05-11 | $24.92M derived: sum of 2 quarters · filed 2026-05-11 | $38.81M derived: sum of 3 quarters · filed 2026-05-11 | $53.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $26.80M derived: sum of 2 quarters · filed 2026-02-24 | $41.01M derived: sum of 3 quarters · filed 2026-08-05 | $55.79M 10-K · filed 2026-02-24 |
| 2025-09-30 | $13.89M 10-Q · filed 2025-11-06 | $28.10M derived: sum of 2 quarters · filed 2026-08-05 | $42.89M 10-Q · filed 2025-11-06 | $58.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $14.21M 10-Q · filed 2026-08-05 | $28.99M 10-Q · filed 2026-08-05 | $44.22M derived: sum of 3 quarters · filed 2026-08-05 | $61.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $14.79M 10-Q · filed 2026-05-11 | $30.01M derived: sum of 2 quarters · filed 2026-05-11 | $47.18M derived: sum of 3 quarters · filed 2026-05-11 | $64.96M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $15.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $32.39M derived: sum of 2 quarters · filed 2026-02-24 | $50.17M derived: sum of 3 quarters · filed 2026-02-24 | $67.58M 10-K · filed 2026-02-24 |
| 2024-09-30 | $17.16M 10-Q · filed 2025-11-06 | $34.95M derived: sum of 2 quarters · filed 2025-11-06 | $52.35M 10-Q · filed 2025-11-06 | $68.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $17.78M 10-Q · filed 2025-08-07 | $35.19M 10-Q · filed 2025-08-07 | $51.64M derived: sum of 3 quarters · filed 2026-02-24 | $67.50M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $17.41M 10-Q · filed 2025-05-08 | $33.86M derived: sum of 2 quarters · filed 2026-02-24 | $49.72M derived: sum of 3 quarters · filed 2026-02-24 | $66.12M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $32.31M derived: sum of 2 quarters · filed 2026-02-24 | $48.71M derived: sum of 3 quarters · filed 2026-02-24 | $64.18M 10-K · filed 2026-02-24 |
| 2023-09-30 | $15.86M 10-Q · filed 2024-11-04 | $32.26M derived: sum of 2 quarters · filed 2024-11-04 | $47.73M 10-Q · filed 2024-11-04 | $61.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $16.40M 10-Q · filed 2024-08-06 | $31.87M 10-Q · filed 2024-08-06 | $45.20M derived: sum of 3 quarters · filed 2025-02-27 | $56.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $15.47M 10-Q · filed 2024-05-07 | $28.80M derived: sum of 2 quarters · filed 2025-02-27 | $40.55M derived: sum of 3 quarters · filed 2025-02-27 | $52.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $13.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $25.08M derived: sum of 2 quarters · filed 2025-02-27 | $37.19M derived: sum of 3 quarters · filed 2025-02-27 | $49.48M 10-K · filed 2025-02-27 |
| 2022-09-30 | $11.75M 10-Q · filed 2023-11-02 | $23.87M derived: sum of 2 quarters · filed 2023-11-02 | $36.16M 10-Q · filed 2023-11-02 | $45.20M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $12.11M 10-Q · filed 2023-08-03 | $24.40M 10-Q · filed 2023-08-03 | $33.44M derived: sum of 3 quarters · filed 2024-02-20 | $41.15M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $12.29M 10-Q · filed 2023-05-04 | $21.33M derived: sum of 2 quarters · filed 2024-02-20 | $29.04M derived: sum of 3 quarters · filed 2024-02-20 | $37.51M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $16.75M derived: sum of 2 quarters · filed 2024-02-20 | $25.22M derived: sum of 3 quarters · filed 2024-02-20 | $30.65M 10-K · filed 2024-02-20 |
| 2021-09-30 | $7.71M 10-Q · filed 2022-11-08 | $16.18M derived: sum of 2 quarters · filed 2022-11-08 | $21.61M 10-Q · filed 2022-11-08 | $26.23M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $8.47M 10-Q · filed 2022-08-09 | $13.90M 10-Q · filed 2022-08-09 | $18.52M derived: sum of 3 quarters · filed 2023-02-21 | $20.45M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $5.43M 10-Q · filed 2022-05-10 | $10.05M derived: sum of 2 quarters · filed 2023-02-21 | $11.98M derived: sum of 3 quarters · filed 2023-02-21 | $12.59M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $6.55M derived: sum of 2 quarters · filed 2023-02-21 | $7.16M derived: sum of 3 quarters · filed 2023-02-21 | $8.40M 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.93M 10-Q · filed 2021-11-10 | $2.54M derived: sum of 2 quarters · filed 2021-11-10 | $3.78M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $606.00K 10-Q · filed 2021-08-13 | $1.84M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.24M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $890.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |